Matthew Nour
Consultant Psychiatrist and Senior Clinical Researcher at the University of Oxford
Data updated
Research Footprint
Matthew Nour appears in 6 tracked papers (2016–2022), most studied alongside Psilocybin and DMT, across Depressive Disorders, Major Depressive Disorder (MDD) and Personality & Trait Factors.
Most-cited paper: Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI) (475 citations).
Frequent co-authors: Robin Carhart-Harris, David Nutt and Leor Roseman.
Background & Research
Matthew Nour is a psychiatrist and neuroscientist trained at the University of Oxford, with postgraduate clinical and research appointments across Oxford, King’s College London, Imperial College London, and UCL. His research has focused on computational psychiatry, psychosis, and the neuroscience of psychedelic experiences. He is currently a Senior Clinical Researcher and Consultant Psychiatrist at the University of Oxford.
Key Impact
He is a leading clinician-scientist in psychiatry and computational neuroscience whose work includes foundational psychedelic papers on ego-dissolution, self-experience, and personality change.
Collaboration Network
16 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Matthew Nour is associated with.
University of Oxford Department of Psychiatry
The Department of Psychiatry at the University of Oxford is a clinical department within the Medical Sciences Division that conducts research, teaching, and clinical trials across psychiatry, neuroscience, and mental health. It is based at the Warneford Hospital site in Oxford, England.
View stakeholder →University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →South London and Maudsley NHS Foundation Trust
South London and Maudsley NHS Foundation Trust (SLaM) is the UK's leading academic mental health Trust, home to Maudsley Hospital and the NIHR Maudsley Biomedical Research Centre; in partnership with COMPASS Pathways and King's College London's Institute of Psychiatry, it has established a dedicated Psychedelics and Mental Health Research Centre conducting psilocybin Phase 3 trials for treatment-resistant depression, MDMA therapy for PTSD, 5-MeO-DMT studies, and the SIGNATURE synaptic imaging biomarker trial, aiming to treat 650–700 patients over five years.
View stakeholder →King's College London
academicThe Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
View stakeholder →Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →